Evidence map›Paper›PMID 32935095›Full record

ArticlebioRxiv : the preprint server for biology2020

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro.

Zijun Wang, Julio C C Lorenzi, Frauke Muecksch, Shlomo Finkin, Charlotte Viant, Christian Gaebler, Melissa Cipolla, Hans-Heinrich Hoffman, Thiago Y Oliveira, Deena A Oren and 10 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 39 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 2 countries.

Zijun WangLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Julio C C LorenziLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Frauke MueckschLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Shlomo FinkinLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Charlotte ViantLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Christian GaeblerLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Melissa CipollaLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Hans-Heinrich HoffmanLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Thiago Y OliveiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Deena A OrenStructural Biology Resource Center, The Rockefeller University, New York, NY 10065, USA.
Victor RamosLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Lilian NogueiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Eleftherios MichailidisLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Davide F RobbianiInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Anna GazumyanLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Rockefeller University · USHoward Hughes Medical Institute · USUniversità della Svizzera italiana · CH

Funding

Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Understanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI RAVETCH, JEFFREY VICTOR · 2014 to 2023
$26.0M
Type I interferon-stimulated genes and the antiviral immune responseR01AI091707 · NIAID · ROCKEFELLER UNIVERSITY · PI RICE, CHARLES M · 2011 to 2020
$5.5M
NCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI091707NIAID NIH HHS U19 AI111825
6 · The paper itself

Abstract

SARS-CoV-2 primarily infects cells at mucosal surfaces. Serum neutralizing antibody responses are variable and generally low in individuals that suffer mild forms of the illness. Although potent IgG antibodies can neutralize the virus, less is known about secretory antibodies such as IgA that might impact the initial viral spread and transmissibility from the mucosa. Here we characterize the IgA response to SARS-CoV-2 in a cohort of 149 individuals. IgA responses in plasma generally correlate with IgG responses and clones of IgM, IgG and IgA producing B cells that are derived from common progenitors are evident. Plasma IgA monomers are 2-fold less potent than IgG equivalents. However, IgA dimers, the primary form in the nasopharynx, are on average 15 times more potent than IgA monomers. Thus, secretory IgA responses may be particularly valuable for protection against SARS-CoV-2 and for vaccine efficacy.

Identifiers

PMID32935095
PMCPMC7491508
OpenAlexW3083815322

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.